Patents by Inventor Alfonso QUINTÁS-CARDAMA

Alfonso QUINTÁS-CARDAMA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20230065936
    Abstract: Disclosed herein are methods for treatment of a mesothelin (MSLN)-expressing cancer in a human subject comprising administration of, e.g., a plurality of anti-MSLN T cell receptor fusion protein (TFP)-expressing T cells. A ratio of CD4+ to CD8+ T cells in a sample from the human subject may have been determined before the administration of the plurality of anti-MSLN TFP-expressing T cells. The plurality of anti-MSLN TFP-expressing T cells may comprise a pre-determined ratio of CD4+ to CD8+ T cells.
    Type: Application
    Filed: April 8, 2022
    Publication date: March 2, 2023
    Inventors: Alfonso QUINTÁS-CARDAMA, Robert HOFMEISTER, Robert TIGHE
  • COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
    Publication number: 20220347214
    Abstract: Disclosed herein are dosage and administration methods for treatment of a mesothelin-expressing cancer in a human comprising administration of, e.g., a plurality of anti-mesothelin T cell receptor fusion protein-expressing T cells.
    Type: Application
    Filed: March 20, 2020
    Publication date: November 3, 2022
    Inventor: Alfonso QUINTAS-CARDAMA
  • COMBINATION THERAPIES OF CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS
    Publication number: 20190151365
    Abstract: Provided are compositions and methods for treating diseases, e.g., cancers, e.g., diseases associated with expression of an antigen, e.g., CD 19, comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to the antigen, e.g., CD19, in combination with a PD-1 inhibitor.
    Type: Application
    Filed: July 28, 2017
    Publication date: May 23, 2019
    Applicants: Novartis AG, The Trustees of the University of Pennsylvania, The Trustees of the University of Pennsylvania
    Inventors: Oezlem Anak, Sanela Bilic, Jennifer Brogdon, John Scott Cameron, William Chou, Stephan Grupp, Danny Roland Howard, Jr., Randi Isaacs, Carl H. June, Simon Lacey, Shannon Maude, Jan J. Melenhorst, Stephen Shuster, Alfonso Quintas-Cardama
  • Methods of Identifying and Treating Individuals Exhibiting NUP214-ABL1 Positive T-Cell Malignancies with Protein Tyrosine Kinase Inhibitors and Combinations Thereof
    Publication number: 20110263609
    Abstract: The invention described herein relates to diagnostic and treatment methods and compositions useful in the management of disorders, for example cancers, involving NUP214-ABL1 positive T-cell malignancies and methods for treating an individual suffering from a NUP214-ABL1 positive T cell malignancy.
    Type: Application
    Filed: November 14, 2008
    Publication date: October 27, 2011
    Inventors: Alfonso Quintas-Cardama Lee, Guillermo Garcia-Manero